Doxorubicin Pharmacokinetic (PK) Study

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Cancer

In brief

This protocol is designed to obtain detailed information on the impact of body composition on the pharmacokinetic behavior of doxorubicin after a single intravenous dose in children 21 years of age or younger. There is no efficacy component. Approximately 9 children will be enrolled at Children's Hospital Boston. The information gained from this study could be very important in developing dosing strategies for doxorubicin in the obese patient population.

Key facts

Study ID
NCT00124956
Run by
Boston Children's Hospital
People needed
0
Starts
2003-06-01
Last updated by the study team
2017-09-11

Who can join

Age: 1 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.